PRESS RELEASE published on 10/17/2024 at 18:00, 1 year 5 months ago THERANEXUS JOINS UP WITH SYNERLAB TO PREPARE THE COMMERCIALIZATION OF ITS PEDIATRIC FORMULATION IN NIEMANN-PICK TYPE C DISEASE Theranexus partners with Synerlab to produce oral solution of miglustat for Niemann-Pick type C disease, aiming for EMA approval and commercialization by 2026. Novel pediatric formulation Mig-OS provides new therapeutic option for NPC patients Theranexus Synerlab Miglustat Niemann-Pick Type C Disease EMA Approval
BRIEF published on 09/26/2024 at 18:05, 1 year 5 months ago Theranexus annonce ses résultats financiers du premier semestre 2024 Résultats Financiers Biopharmaceutique Réduction Des Coûts Theranexus Batten-1
BRIEF published on 09/26/2024 at 18:05, 1 year 5 months ago Theranexus announces its financial results for the first half of 2024 Financial Results Cost Reduction Biopharmaceutical Theranexus Batten-1
PRESS RELEASE published on 09/26/2024 at 18:00, 1 year 5 months ago THERANEXUS ANNONCE SES RÉSULTATS FINANCIERS DU PREMIER SEMESTRE 2024 Theranexus, société biopharmaceutique, annonce ses résultats semestriels 2024. Baisse significative des charges d'exploitation grâce à la fin d'essais cliniques et efforts de réduction des coûts Résultats Semestriels Biopharmaceutique Réduction Des Coûts Theranexus Maladies Neurologiques
PRESS RELEASE published on 09/26/2024 at 18:00, 1 year 5 months ago THERANEXUS ANNOUNCES FIRST HALF 2024 FINANCIAL RESULTS Theranexus reports cost reduction success and positive first half 2024 financial results, led by completion of Batten-1 clinical trial and operating grants Financial Results Cost Reduction Clinical Trial Theranexus Batten-1
BRIEF published on 07/11/2024 at 18:50, 1 year 8 months ago Theranexus annonce sa trésorerie au 30 juin 2024 et détaille le progrès de Batten-1 Financement Trésorerie Theranexus Batten-1 Maladie Neurologique
BRIEF published on 07/11/2024 at 18:50, 1 year 8 months ago Theranexus announces its cash flow as of June 30, 2024 and details the progress of Batten-1 Treasury Funding Theranexus Batten-1 Neurological Disease
PRESS RELEASE published on 07/11/2024 at 18:45, 1 year 8 months ago Theranexus publie sa trésorerie au 30 juin 2024 et fait le point sur l'avancement de Batten-1 Theranexus publie sa trésorerie au 30 juin 2024, avance sur Batten-1 et ouvre nouvelle ligne de financement en fonds propres. Commercialisation phase 3 Batten-1 en vue Financement Trésorerie Fonds Propres Theranexus Batten-1
PRESS RELEASE published on 07/11/2024 at 18:45, 1 year 8 months ago Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1 Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF published on 07/03/2024 at 07:35, 1 year 8 months ago Theranexus, CRNL et CERMEP lauréats du projet "Pacte de recherche 2024" d'Auvergne-Rhône-Alpes Recherche Auvergne-Rhône-Alpes Theranexus Neurologie Neuroimagerie
Published on 03/20/2026 at 13:30, 2 days 7 hours ago Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 2 days 8 hours ago CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/22/2026 at 12:23, 8 hours 33 minutes ago Borussia Dortmund and Sebastian Kehl are ending their collaboration with immediate effect
Published on 03/20/2026 at 22:45, 1 day 22 hours ago Investor Alert: Berger Montague (Canada) PC represents investors that purchased shares of Super Micro Computer, Inc. listed on the CBOE Canada and elsewhere
Published on 03/20/2026 at 21:05, 1 day 23 hours ago Fractal EMS Receives ISO/IEC 9001 and 27001 Certifications
Published on 03/20/2026 at 21:05, 1 day 23 hours ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $4.3 billion
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 1 hour ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 2 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 2 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA